Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05048108 · ClinicalTrials.gov registry record

Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors

A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.

Completed
Registry status
65
Enrollment target

NCT05048108 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 65 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05048108 has completed, sponsored by Ohio State University Comprehensive Cancer Center.

COMPLETED
Registry status
65 participants
Enrollment target

Study Summary

Majority of breast cancer survivors are overweight or obese at time of diagnosis, putting them at increased risk for insulin resistance and Type 2 Diabetes Mellitus (T2DM). Women with insulin resistance at time of breast cancer diagnosis often have larger tumors, later stages of cancer and worse prognosis. Additionally, chemotherapy often leads to increases in insulin resistance and cognitive impairment. Many cancer survivors experience memory and brain function decline following chemotherapy that can last for years, and insulin resistance may contribute to worse cognitive outcomes in cancer survivors. Omega-3 polyunsaturated fatty acids (PUFAs) are anti-inflammatory nutrients that may help reduce insulin resistance and negative cognitive outcomes from cancer treatments. The purpose of this observational study with cross-sectional design is to investigate the relationship of omega-3 PUFAs with insulin resistance and cognitive function in obese breast cancer survivors. Due to the global pandemic caused by the coronavirus disease of 2019 (COVID-19), this study will be conducted entirely remotely using electronic data collection and remote finger-stick blood sample collection. The study will aim to enroll 80 racially and ethnically diverse female breast cancer survivors (age 45-75) who are postmenopausal, and 1 to 4 years post breast cancer diagnosis. Participants will complete study questionnaires online, and some cognitive tests will be completed through zoom sessions with trained study personnel. Participants will be mailed kits with thorough instructions to complete fingerstick blood sample collections and mail them back to the research lab. Upon receipt of blood samples and completion of all study questionnaires, participation will be complete.

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2022-01-18
Est. Completion 2023-11-30

What the Registry Record Tells You About NCT05048108

The ClinicalTrials.gov registry entry for NCT05048108 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT05048108 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05048108 about?

NCT05048108 is a clinical study titled "Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors". Majority of breast cancer survivors are overweight or obese at time of diagnosis, putting them at increased risk for insulin resistance and Type 2 Diabetes Mellitus (T2DM). Women with insulin resistance at time of breast cancer diagnosis often have larger tumors, later stages of cancer and worse pro...

What is the current status of trial NCT05048108?

This trial is currently completed. The enrollment target is 65 participants. The study started on 2022-01-18. Estimated completion is 2023-11-30.

Who is sponsoring clinical trial NCT05048108?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.